Loading...

Actinic Keratosis Treatment Market by Drug Type (Fluorouracil, Imiquimod, Diclofenac, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026

A05989
Pages: 235
Feb 2020 | 2273 Views
 
Author(s) : Sayali Shinde , Onkar Sumant
Tables: 104
Charts: 54
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Actinic Keratosis Treatment Market

Request Now !

The global actinic keratosis treatment market was valued at $1,117 million in 2018, and is projected to reach $1,558 million by 2026, registering a CAGR of 4.2% from 2019 to 2026.  

Actinic keratosis (AK) is the most common precancer that forms on skin damaged by long-term exposure to ultraviolet radiation from the sun and/or indoor tanning. It is characterized by rough, scaly patch on skin most commonly found on your face, lips, ears, back of your hands, forearms, scalp, or neck. Surgical procedures, topical treatments, photodynamic therapy, and combination therapy are used for the treatment of actinic keratosis. Drug such as 5-fluorouracil, diclofenac, imiquimod, and ingenol mebutate have been approved for the treatment of actinic keratosis. 

Actinic Keratosis Treatment

Get more information on this report : Request Sample Pages

 

Increase in prevalence of actinic keratosis, preferable use of topical therapeutics, potential drugs in pipeline, rise in demand for actinic keratosis treatment products, growth in geriatric population, and wide availability of therapeutics are the major factors that drive the growth of the actinic keratosis treatment market. For instance, according to the Skin Cancer Foundation, actinic keratosis is the most common precancer and it affects more than 58 million Americans. In addition, according to article published in News Medical the overall rate of actinic keratosis in the U.S. is estimated to be approximately 10.2% in females and 26.5% in males. In addition, increase in adoption of topical treatment for actinic keratosis, easy accessibility to therapeutics, and rise in healthcare expenditure are other factors that contribute toward the growth of the market. Potential pipeline drugs are AM-001, GDC 695, Tirbanibulin, Tuvatexib and others will further drive the market growth. However, availability of alternate treatment is expected to hinder the market growth. 

Actinic Keratosis Treatment Market Segmentation  

The actinic keratosis treatment market is segmented on the basis of drug type, type, distribution channel, and region. By drug type, the market is categorized into fluorouracil, imiquimod, diclofenac, and others. On the basis of type, the market is bifurcated into prescription and OTC. According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 

Segment Review 

Based on drug type, the market is segmented into fluorouracil, imiquimod, diclofenac, and others. Presently fluorouracil segment dominates the global market, and is anticipated to continue this trend over the forecast period. The key factors that drive the market growth include use of fluorouracil as a first line treatment, increase in demand & cost effectivity, and wide availability of fluorouracil act as the key factors that significantly contribute toward the growth of the market. 

Actinic Keratosis Treatment Market
By Drug Type

Your browser does not support the canvas element.

Imiquimod is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online pharmacy, and rise in number of internet users. 

Actinic Keratosis Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Drug Stores And Retail Pharmacies holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific Actinic Keratosis Treatment Market  

Asia-Pacific presents lucrative opportunities for the key players operating in the actinic keratosis treatment market. Some key factors such as increase in awareness toward actinic keratosis treatment, growth in prevalence of actinic keratosis, improvement in healthcare infrastructure, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare are contributing toward the market growth in this region. 

In addition, surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market is expected to drive the growth of the actinic keratosis treatment market in Asia-Pacific.

Actinic Keratosis Treatment Market
By Geography

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 6.3% during 2019-2026.

Get more information on this report : Request Sample Pages

The key players profiled in this report include 3M Company, Almirall, S.A., Bausch Health Companies Inc., Biofrontera, Inc., Hill Dermaceuticals, Inc., LEO Pharma A/S, Mylan N.V., Novartis AG, Stanford Chemicals, and Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.). 

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis of the actinic keratosis treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers Actinic keratosis treatment market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of all the major geographical regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global actinic keratosis treatment market growth.

Key Market Segments:

By Drug Type 

  • Fluorouracil
  • Imiquimod
  • Diclofenac
  • Others 

By Type 

  • Prescription 
  • OTC 

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018

3.3. Porter’s five force analysis
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of actinic keratosis
3.4.1.2. Potential drugs present in pipeline
3.4.1.3. Increase in government expenditure on healthcare

3.4.2. Restraint

3.4.2.1. Availability of alternate treatment options

3.4.3. Opportunities

3.4.3.1. Growth opportunities in emerging markets

3.4.4. Impact analysis

CHAPTER 4: ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Fluorouracil

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Imiquimod

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

4.4. Diclofenac

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

4.5. Others

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country

CHAPTER 5: ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Prescription

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. OTC

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals pharmacies

6.2.1. Market size and forecast
6.2.2. Market analysis, by country

6.3. Drug stores and retail pharmacies

6.3.1. Market size and forecast
6.3.2. Market analysis, by country

6.4. Online providers

6.4.1. Market size and forecast
6.4.2. Market analysis, by country

CHAPTER 7: ACTINIC KERATOSIS TREATMENT MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. actinic keratosis treatment market, by drug type
7.2.2.1.2. U.S. actinic keratosis treatment market, by type
7.2.2.1.3. U.S. actinic keratosis treatment market, by distribution channel

7.2.2.2. Canada

7.2.2.2.1. Canada actinic keratosis treatment market, by drug type
7.2.2.2.2. Canada actinic keratosis treatment market, by type
7.2.2.2.3. Canada actinic keratosis treatment market, by distribution channel

7.2.2.3. Mexico

7.2.2.3.1. Mexico actinic keratosis treatment market, by drug type
7.2.2.3.2. Mexico actinic keratosis treatment market, by type
7.2.2.3.3. Mexico actinic keratosis treatment market, by distribution channel

7.2.3. North America market size and forecast, by drug type
7.2.4. North America actinic keratosis treatment market, by type
7.2.5. North America actinic keratosis treatment market, by distribution channel

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Germany actinic keratosis treatment market, by drug type
7.3.2.1.2. Germany actinic keratosis treatment market, by type
7.3.2.1.3. Germany actinic keratosis treatment market, by distribution channel

7.3.2.2. France

7.3.2.2.1. France actinic keratosis treatment market, by drug type
7.3.2.2.2. France actinic keratosis treatment market, by type
7.3.2.2.3. France actinic keratosis treatment market, by distribution channel

7.3.2.3. UK

7.3.2.3.1. UK actinic keratosis treatment market, by drug type
7.3.2.3.2. UK actinic keratosis treatment market, by type
7.3.2.3.3. UK actinic keratosis treatment market, by distribution channel

7.3.2.4. Italy

7.3.2.4.1. Italy actinic keratosis treatment market, by drug type
7.3.2.4.2. Italy actinic keratosis treatment market, by type
7.3.2.4.3. Italy actinic keratosis treatment market, by distribution channel

7.3.2.5. Spain

7.3.2.5.1. Spain actinic keratosis treatment market, by drug type
7.3.2.5.2. Spain actinic keratosis treatment market, by type
7.3.2.5.3. Spain actinic keratosis treatment market, by distribution channel

7.3.2.6. Rest of Europe

7.3.2.6.1. Rest of Europe actinic keratosis treatment market, by drug type
7.3.2.6.2. Rest of Europe actinic keratosis treatment market, by type
7.3.2.6.3. Rest of Europe actinic keratosis treatment market, by distribution channel

7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe actinic keratosis treatment market, by type
7.3.5. Europe actinic keratosis treatment market, by distribution channel

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Japan actinic keratosis treatment market, by drug type
7.4.2.1.2. Japan actinic keratosis treatment market, by type
7.4.2.1.3. Japan actinic keratosis treatment market, by distribution channel

7.4.2.2. China

7.4.2.2.1. China actinic keratosis treatment market, by drug type
7.4.2.2.2. China actinic keratosis treatment market, by type
7.4.2.2.3. China actinic keratosis treatment market, by distribution channel

7.4.2.3. Australia

7.4.2.3.1. Australia actinic keratosis treatment market, by drug type
7.4.2.3.2. Australia actinic keratosis treatment market, by type
7.4.2.3.3. Australia actinic keratosis treatment market, by distribution channel

7.4.2.4. Rest of Asia-Pacific

7.4.2.4.1. Rest of Asia-Pacific actinic keratosis treatment market, by drug type
7.4.2.4.2. Rest of Asia-Pacific actinic keratosis treatment market, by type
7.4.2.4.3. Rest of Asia-Pacific actinic keratosis treatment market, by distribution channel

7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific actinic keratosis treatment market, by type
7.4.5. Asia-Pacific actinic keratosis treatment market, by distribution channel

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil actinic keratosis treatment market, by drug type
7.5.2.1.2. Brazil actinic keratosis treatment market, by type
7.5.2.1.3. Brazil actinic keratosis treatment market, by distribution channel

7.5.2.2. Saudi Arabia

7.5.2.2.1. Saudi Arabia actinic keratosis treatment market, by drug type
7.5.2.2.2. Saudi Arabia actinic keratosis treatment market, by type
7.5.2.2.3. Saudi Arabia actinic keratosis treatment market, by distribution channel

7.5.2.3. South Africa

7.5.2.3.1. South Africa actinic keratosis treatment market, by drug type
7.5.2.3.2. South Africa actinic keratosis treatment market, by type
7.5.2.3.3. South Africa actinic keratosis treatment market, by distribution channel

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA actinic keratosis treatment market, by drug type
7.5.2.4.2. Rest of LAMEA actinic keratosis treatment market, by type
7.5.2.4.3. Rest of LAMEA actinic keratosis treatment market, by distribution channel

7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA actinic keratosis treatment market, by type
7.5.5. LAMEA actinic keratosis treatment market, by distribution channel

CHAPTER 8: COMPANY PROFILES

8.1. 3M Company

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. Almirall, S.A.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Bausch Health Companies Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance

8.4. Biofrontera, Inc.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. Hill Dermaceuticals, Inc.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments

8.6. LEO Pharma A/S

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. Mylan N.V

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance

8.8. Novartis AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance

8.9. Stanford Chemicals

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio

8.10. Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.)

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 02. FLUOROURACIL ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. IMIQUIMOD ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. DICLOFENAC ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 07. PRESCRIPTION ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTC ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 10. ACTINIC KERATOSIS TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 11. ACTINIC KERATOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 12. ACTINIC KERATOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2018–2026 ($MILLION)
TABLE 13. ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 14. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 15. U.S. ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 16. U.S. ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 17. U.S. ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 18. CANADA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 19. CANADA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 20. CANADA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 21. MEXICO ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 22. MEXICO ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 23. MEXICO ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 24. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 25. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 26. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 27. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 28. GERMANY ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 29. GERMANY ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 30. GERMANY ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 31. FRANCE ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 32. FRANCE ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 33. FRANCE ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 34. UK ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 35. UK ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 36. UK ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 37. ITALY ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 38. ITALY ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 39. ITALY ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 40. SPAIN ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 41. SPAIN ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 42. SPAIN ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 43. REST OF EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 44. REST OF EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 45. REST OF EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 46. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 47. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 48. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 49. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 50. JAPAN ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 51. JAPAN ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 52. JAPAN ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 53. CHINA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 54. CHINA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 55. CHINA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 56. AUSTRALIA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 57. AUSTRALIA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 58. AUSTRALIA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 59. REST OF ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 60. REST OF ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 61. REST OF ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 62. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 63. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 64. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 65. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 66. BRAZIL ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 67. BRAZIL ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 68. BRAZIL ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 69. SAUDI ARABIA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 70. SAUDI ARABIA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 71. SAUDI ARABIA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 72. SOUTH AFRICA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 73. SOUTH AFRICA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 74. SOUTH AFRICA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 75. REST OF LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 76. REST OF LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 77. REST OF LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 78. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 79. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 80. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 81. 3M COMPANY: COMPANY SNAPSHOT
TABLE 82. 3M COMPANY: OPERATING SEGMENTS
TABLE 83. 3M COMPANY: PRODUCT PORTFOLIO
TABLE 84. ALMIRALL: COMPANY SNAPSHOT
TABLE 85. ALMIRALL: PRODUCT PORTFOLIO
TABLE 86. BAUSCH HEALTH: COMPANY SNAPSHOT
TABLE 87. BAUSCH HEALTH: OPERATING SEGMENTS
TABLE 88. BAUSCH HEALTH: PRODUCT PORTFOLIO
TABLE 89. BIOFRONTERA: COMPANY SNAPSHOT
TABLE 90. BIOFRONTERA: PRODUCT PORTFOLIO
TABLE 91. HD: COMPANY SNAPSHOT
TABLE 92. HD: PRODUCT PORTFOLIO
TABLE 93. LEO PHARMA: COMPANY SNAPSHOT
TABLE 94. LEO PHARMA: PRODUCT PORTFOLIO
TABLE 95. MYLAN: COMPANY SNAPSHOT
TABLE 96. MYLAN: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS: COMPANY SNAPSHOT
TABLE 98. NOVARTIS: OPERATING SEGMENTS
TABLE 99. NOVARTIS: PRODUCT PORTFOLIO
TABLE 100. STANFORD CHEMICALS: COMPANY SNAPSHOT
TABLE 101. STANFORD CHEMICALS: PRODUCT PORTFOLIO
TABLE 102. SUN PHARMA: COMPANY SNAPSHOT
TABLE 103. SUN PHARMA: OPERATING SEGMENTS
TABLE 104. SUN PHARMA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL ACTINIC KERATOSIS TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET PLAYER POSITIONING, 2018
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE COMPETITIVE RIVALRY
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. COMPARATIVE ANALYSIS OF FLUOROURACIL ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF IMIQUIMOD ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF DICLOFENAC ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF OTHERS ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF PRESCRIPTION ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF OTC ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF ACTINIC KERATOSIS TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF ACTINIC KERATOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF ACTINIC KERATOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 19. U.S. ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 20. CANADA ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 21. MEXICO ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 22. GERMANY ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 23. FRANCE ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 24. UK ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 25. ITALY ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 26. SPAIN ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 27. REST OF EUROPE ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 28. JAPAN ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 29. CHINA ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 30. AUSTRALIA ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 31. REST OF ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 32. BRAZIL ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 33. SAUDI ARABIA ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 34. SOUTH AFRICA ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 35. REST OF LAMEA ACTINIC KERATOSIS TREATMENT MARKET, 2018 TO 2026 ($MILLION)
FIGURE 36. 3M COMPANY: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. 3M COMPANY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. 3M COMPANY: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39. ALMIRALL: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. ALMIRALL: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 41. BAUSCH HEALTH: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. BAUSCH HEALTH: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 43. BAUSCH HEALTH: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 44. BIOFRONTERA: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. BIOFRONTERA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 46. LEO PHARMA: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. LEO PHARMA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 49. MYLAN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 50. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 52. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 53. SUN PHARMA: NET SALES, 2016–2018 ($MILLION)
FIGURE 54. SUN PHARMA: REVENUE SHARE BY REGION, 2018 (%)

 
 

Actinic keratosis is most commonly found on face, lips, ears, back of your hands, forearms, scalp, and neck. Actinic keratosis can be treated using different therapies such as surgical procedures, topical treatments, photodynamic therapy, and combination therapy. However, topical therapeutics such as fluorouracil, imiquimod, and diclofenac are preferably used in the treatment.

Surge in R&D for the innovation of new products and preferable use of actinic keratosis topical treatment significantly boost the growth of the actinic keratosis treatment market. Moreover, rise in geriatric population, growth in incidence of actinic keratosis, and rise in adoption of topical treatments further drive the market growth. However, availability of alternative treatments are expected to restrain the growth of the market.

North America is expected to remain dominant during the forecast period due to higher prevalence of actinic keratosis with increase in healthcare awareness and presence of pipeline drugs under various stages of clinical trials. In addition, Asia-Pacific are expected to offer lucrative opportunities to the key players during the forecast period due to rise in prevalence of actinic keratosis in countries such as Australia and New Zealand.

 

 

 

 

 

 

 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The market value of global actinic keratosis market was $1,116.7 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global actinic keratosis market in 2019 is $1,165.2 million.

A. The adoption of actinic keratosis is expected to increase in prevalence of actinic keratosis, use of topical therapeutics as a first line treatment option, rise in demand for actinic keratosis therapeutics, strong presence of pipeline drugs, and rise in geriatric population are the key factors that fuel the growth of the actinic keratosis treatment market

A. The base year calculated in the report is 2018.

A. Yes, Novartis is profiled in the report.

A. Emerging countries of Asia-Pacific region are growing at a growth% of 6.3%. Japan, China, Australia, are expected grow at a CAGR of 6.9%, 4.6%, 8.1% respectively.

A. The North America market held a major share in the actinic keratosis market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to rise in demand for actinic keratosis treatment drugs, presence of advanced healthcare facilities with trained medical professionals, and surge in number of R & D activities to develop actinic keratosis therapeutics, thereby contributing toward the growth of the North America market.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Actinic Keratosis Treatment Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts